Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
View Patent ↗The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
1. An antibody composition comprising antibody molecules, wherein 50% or more of the molecules comprise a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region, wherein said sugar chains comprise a reduced terminal which contains an N-acetylglucosamine; wherein said sugar chains do not contain fucose bound to the 6-position of the N-acetylglucosamine in the reducing terminal of the sugar chains; and wherein said antibody molecules bind to CC chemokine receptor 4 (CCR4).
2. The antibody composition according to claim 1 , wherein the antibody molecules are molecules selected from the group consisting of (a), (b), and (c):
(a) human antibodies
(b) humanized antibodies;
(c) antibody fragments.
3. The antibody composition according to claim 1 , wherein the antibody molecules belong to an IgG class.
4. A composition comprising the antibody composition according to claim 1 and a carrier.
5. An antibody composition comprising the antibody molecules according to claim 1 , wherein the antibody molecule is a nonfucosylated anti-CCR4 antibody.